Table 2.
Univariate and multivariate analyses for decline in eGFR (eGFR based on CKD-EPI equation), ESRD, and death for HIV+ CCC individuals, 1998 through 2005
| Baseline Group (N) | Outcome | Events, n | Unadjusted Incidence Rate Ratio AA:non-AA (95% CIs)c | Adjusted HR AA:non-AA (95% CIs)c |
|---|---|---|---|---|
| Total populationa (2468) | eGFR decline and death | 182 | 1.9 (1.4, 2.5) | 1.6 (1.1, 2.3) |
| eGFR decline | 63 | 2.1 (1.3, 3.5) | 1.1 (0.6, 2.1) | |
| death | 126 | 1.7 (1.2, 2.4) | 1.5 (0.9, 2.5) | |
| CKD5/ESRDd | 21 | 4.9 (1.9, 12.2) | 4.5 (1.8, 11.4) | |
| Subgroup analysisa eGFR ≥60 ml/min per 1.73 m2 (2366) | eGFR decline and death | 155 | 1.6 (1.2, 2.2) | 1.2 (0.8, 1.9) |
| eGFR decline | 56 | 1.6 (0.9, 2.9) | 1.1 (0.5, 2.2) | |
| death | 115 | 1.6 (1.1, 2.3) | 1.4 (0.8, 2.3) | |
| Subgroup analysisb eGFR <60 ml/min per 1.73 m2 (102) | eGFR decline and death | 27 | 3.0 (1.4, 6.7) | 1.8 (0.5, 6.1)b |
| eGFR decline | 17 | 3.2 (1.2, 8.8) | 2.5 (0.9, 6.9)b | |
| death | 11 | 1.8 (0.5, 5.7) | 1.9 (0.6, 6.5)b |
Race categorized as HIV+ AA and HIV+ non-AA. HRs reported for AA referent to non-AA.
Total population and eGFR ≥60 ml/min per 1.73 m2 subgroups adjusted for the following baseline covariates: age, absolute CD4 count, HIV-1 RNA, baseline eGFR, race, gender, hypertension, anemia, HAART use, hepatitis C, cardiovascular disease, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, diabetes, intravenous drug use–HIV risk, and opportunistic infection/AIDS-defining event.
All other subgroup analyses based on univariate Cox model due to a small sample size and limited power.
95% CIs reported for the corresponding HR using Cox regression.
CKD5 defined as eGFR ≤15 to 29 ml/min per 1.73 m2; ESRD <15 ml/min per 1.73 m2 or by ICD-9 code.